Navigation Links
Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting

CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.

"We're encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis," remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc.  "Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we're on track for accomplishing that through our unique approach."

The posters will highlight Medac Pharma Inc.'s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:Title:Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector PenTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract #1354Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)Title:Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of MethotrexateTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract # 1355Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)About Medac Pharma, Inc.Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives.  The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

SOURCE Medac Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
2. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
5. NovoBioPharma, Partnership of Top Life Science Experts, Launches
6. Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
7. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
8. Zosano Pharma, Inc. Announces Key Strategic Hire
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
11. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
Post Your Comments:
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... , June 23, 2016  The National Pharmaceutical ... joined the health policy research organization as its ... , MD, senior vice president and chief scientific ... representative on the NPC Board of Directors. ... that Mallinckrodt has joined us in support of ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):